End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.94 CNY | +2.51% | +7.60% | -3.48% |
Apr. 26 | Winning Health Technology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | UBS Upgrades China's 2024 GDP Growth Forecast | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 56% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With a 2024 P/E ratio at 28.04 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.84 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.48% | 2B | C- | ||
-12.23% | 194B | A- | ||
+0.74% | 167B | B+ | ||
+2.19% | 155B | B- | ||
+4.34% | 101B | A- | ||
+7.04% | 76.69B | A- | ||
+19.09% | 72.08B | C- | ||
-7.30% | 71.48B | A | ||
-20.54% | 50.93B | C | ||
+0.53% | 48.89B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300253 Stock
- Ratings Winning Health Technology Group Co., Ltd.